In most of the world, disease burden is shifting toward non-communicable diseases and injuries and is less driven by infectious illnesses. Many countries have seen significant declines in HIV/AIDS, but success has varied across regions and countries. Although the epidemic peaked in magnitude in 2005, HIV/AIDS is still among the top 10 causes of death globally, and nearly 30 million people are living with HIV worldwide.
Our analysis reveals substantial within-country variation in the prevalence of HIV throughout sub-Saharan Africa and local differences in both the direction and rate of change in HIV prevalence between 2000 and 2017, highlighting the degree to which important local differences are masked when examining trends at the country level.
This Visualizing Health Metrics infographic, based on the Global Burden of Disease Study 2013, provides information about HIV incidence, mortality, and prevalence between 1990 and 2013.
HIV/AIDS remains the most common cause of death in sub-Saharan Africa. As of 2017, 71% of the world’s HIV-positive population lived there. Before this study, differences in subnational HIV prevalence (the percentage of people with HIV) and the number of people living with HIV (PLHIV) had not been examined comprehensively across sub-Saharan Africa at high spatial resolution.
Explore local patterns of HIV prevalence from 2000 to 2017 with this interactive visualization tool.
Explore the burden of HIV/AIDS over time and simulate future HIV/AIDS outcomes that could result from scenarios exploring decreases in development assistance funding.
Spending on HIV/AIDS globally between 2000 and 2015 totaled more than half a trillion dollars, according to a new scientific study, the first long-term and comprehensive analysis of funding for the disease.
The objectives of this study were to provide an accurate estimate of antenatal HIV screening and its determinants among pregnant women in El Salvador and help local authorities make informed decisions for targeted interventions around mother-to-child transmission (MTCT).
Previous estimates of the burden of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among people who inject drugs have not included estimates of the burden attributable to the consequences of past injecting. We aimed to provide these estimates as part of the Global Burden of Disease (GBD) Study 2013.
Health facilities in Kenya, Uganda, and Zambia could extend life-sustaining antiretroviral therapy (ART) to hundreds of thousands of people living with HIV if facilities improved the efficiency of service delivery. This is one of the main findings from a paper published today in BMC Medicine, co-authored by the Institute for Health Metrics and Evaluation (IHME) and collaborators from Action Africa Help-International (AAH-I) in Kenya, the Infectious Diseases Research Collaboration (IDRC) in Uganda, and the University of Zambia in Zambia.
Comparable estimates of health spending are crucial for the assessment of health systems and to optimally deploy health resources. The methods used to track health spending continue to evolve, but little is known about the distribution of spending across diseases. We developed improved estimates of health spending by source, including development assistance for health, and, for the first time, estimated HIV/AIDS spending on prevention and treatment and by source of funding, for 188 countries.
Measuring the survival of human immunodeficiency virus–infected adult patients enrolled in antiretroviral therapy (ART) programs is complicated by short observation periods and loss to follow-up. We synthesized data from treatment cohorts in sub-Saharan Africa to estimate survival over 5 years after initiation of ART.
Funding earmarked for improving maternal and child health in low- and middle-income countries has grown faster since 2010 than funding for HIV, TB, and malaria.
We used spending estimates to measure progress in financing the priority areas of SDG 3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG 3 indicators for which data are available.
Health and employment in the context of HIV/AIDS: the long-term economic impacts of antiretroviral therapy.
In order to assess the long-term impact of the global response to HIV/AIDS, it is essential to understand engagement in care over time for the millions of persons living with HIV/AIDS in Africa. However, unacceptably high rates of loss to follow-up (25 to 50% of patients one ye...
AIDS deaths are falling in most countries worldwide, but the rate of new infections increased in several countries over the past decade, threatening to undermine efforts to end the AIDS epidemic by 2030, a new scientific paper shows.
We used the results of the Global Burden of Disease 2015 study to estimate trends of HIV/AIDS burden in Eastern Mediterranean Region (EMR) countries between 1990 and 2015.
Strengthening HIV prevention, care, and treatment in the Democratic Republic of the Congo - addressing structural challenges and promoting real-time data use.